C08229-2023 |
Title of Each Class | Number of Shares of Common Stock Outstanding and Amount of Debt Outstanding | |
---|---|---|
Common | 1,468,471,340 |
The Exchange does not warrant and holds no responsibility for the veracity of the facts and representations contained in all corporate disclosures, including financial reports. All data contained herein are prepared and submitted by the disclosing party to the Exchange, and are disseminated solely for purposes of information. Any questions on the data contained herein should be addressed directly to the Corporate Information Officer of the disclosing party.
Subject of the Disclosure |
---|
PCC Completes Motu Proprio Review on the Acquisition of Rose Pharmacy |
Background/Description of the Disclosure |
On 7 November 2022, the Mergers and Acquisitions Office of the Philippine Competition Commission commenced a motu proprio review of the completed acquisition. After approximately 11 months of review, on 5 October 2023, the Commission en banc resolved to terminate the motu proprio review and take no further action on the completed acquisition, there being no sufficient basis to prohibit the same. The Commission issued the formal certification to this effect on 6 November 2023. |
Other Relevant Information |
Added the information that the Commission issued the formal certification on November 6, 2023 which was received by RRHI on November 6,2023. |
Name | Mylene Kasiban |
---|---|
Designation | Chief Financial Officer |